Eight programmes, one shared platform
Internal and partnered programmes advancing from discovery through clinical evaluation. Stage assignments are reviewed quarterly by our scientific advisory board.
| Programme | Indication | Partner | Stage |
|---|---|---|---|
BB-101 Oncology | Solid tumours — pH-responsive siRNA carrier | Meridian Pharma | IND-enabling |
BB-114 Oncology | Pancreatic adenocarcinoma — stromal-penetrating payload | Undisclosed | Preclinical |
BB-207 Vaccines | Thermostable self-amplifying RNA platform | Nordic Vaccine Institute | IND-enabling |
BB-233 Immunology | Autoimmune modulation — tolerogenic nanoparticle | In-house | Lead opt. |
BB-318 Neurology | CNS oligonucleotide shuttle — neurodegeneration | ETH Molecular Systems | Preclinical |
BB-402 Rare disease | Hepatic enzyme replacement carrier | Helix Therapeutics | Lead opt. |
BB-510 Diagnostics | Multiplexed quantum-dot biomarker panel | Cambridge Nanolab | Clinical |
BB-604 Diagnostics | Point-of-care sepsis early-warning assay | In-house | Preclinical |
Stages: Discovery → Lead optimisation → Preclinical → IND-enabling → Clinical.
How we got here
- 2019
Company founded
Spun out of the Cambridge Nanolab with seed backing and three founding scientists.
- 2021
BrilliantCore™ validated
First peer-reviewed demonstration of pH-tuned endosomal escape in vivo.
- 2023
GMP suite opened
Continuous-flow manufacturing line commissioned for clinical-scale supply.
- 2025
First clinical readout
BB-510 diagnostic panel entered clinical evaluation with a hospital network.
- 2026
Two IND filings
BB-101 and BB-207 progressing through IND-enabling toxicology.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.